Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.12 USD | +6.97% | +5.68% | -13.30% |
05:42pm | Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating | MT |
10:35am | Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.30% | 1.37B | |
+45.68% | 54.63B | |
-6.62% | 39.92B | |
+37.07% | 38.82B | |
+13.40% | 26.86B | |
-11.17% | 26.22B | |
-21.72% | 18.78B | |
+25.72% | 12.21B | |
+0.61% | 12.16B | |
+25.65% | 11.94B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Transcript : Arcus Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024